PositiveID Engages American Capital Ventures for Investor Relations Services
January 07 2014 - 8:30AM
PositiveID Corporation ("PositiveID") (OTCQB:PSID), a developer of
biological detection and diagnostics solutions, today announced
that it has engaged American Capital Ventures, a boutique provider
of comprehensive investor relations, financial marketing and
capital advisory services to the micro- and small-cap community.
"I am pleased to announce our engagement with American Capital
Ventures, a provider of investor relations services to emerging
growth companies like ours," commented William J. Caragol, Chairman
and CEO of PositiveID. "Over the course of the last year and a
half, we have been working diligently to reposition the business to
better capitalize on sales and partnership opportunities for both
our M-BAND airborne bio-threat detector and Firefly handheld,
PCR-based diagnostics device. We are eager to showcase the immense
market potential for our molecular diagnostics solutions to
investment and analyst communities. American Capital Ventures has
been brought on board to assist in this initiative and we believe
they will be instrumental in communicating our opportunity to the
proper audience and generating greater awareness among
investors."
Howard Gostfrand, President of American Capital Ventures,
commented, "At the crux of PositiveID is the unwavering
determination to help protect U.S. citizens from biological
threats. Their M-BAND system is positioned to help our homeland
defense teams do just that, while Firefly extends the ability to
perform biological testing at the point of need – quickly. We are
excited to be working with Bill and his top-notch team on better
informing the public and the investment community of the potential
of their revolutionary technology and securing the long-term
investors needed to get PositiveID to the next level."
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and
developer of biological detection systems for America's homeland
defense industry as well as rapid biological testing. PositiveID is
focused on the development of microfluidic systems for the
automated preparation of and performance of biological assays in
order to detect biological threats at high-value locations, as well
as analyze samples in a medical environment. For more information
on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the
likelihood that there is immense market potential for PositiveID's
molecular diagnostics solutions and that American Capital Ventures
will be undoubtedly instrumental in communicating PositiveID's
opportunity to the proper audience and generating greater awareness
among investors, constitute "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934, and as that term is defined
in the Private Litigation Reform Act of 1995. Such forward-looking
statements involve risks and uncertainties and are subject to
change at any time, and PositiveID's actual results could differ
materially from expected results. Additional information about
these and other factors that could affect the Company's business is
set forth in the Company's various filings with the Securities and
Exchange Commission, including those set forth in the Company's
10-K filed on April 16, 2013, and 10-Qs filed on May 20, 2013,
August 14, 2013, as amended August 19, 2013, and November 19, 2013,
under the caption "Risk Factors." The Company undertakes no
obligation to update or release any revisions to these
forward-looking statements to reflect events or circumstances after
the date of this statement or to reflect the occurrence of
unanticipated events, except as required by law.
CONTACT: PositiveID Corporation
Allison Tomek
561-805-8000
atomek@positiveidcorp.com